Immunochromatographic strips (ICSs) are a practical tool commonly used in point-of-care testing (POCT) applications. However, ICSs that are currently available have low sensitivity and require expensive equipment for quantitative analysis. These limitations prohibit their extensive use in areas where medical resources are scarce. We developed a novel POCT platform by integrating a gas generation biosensor with Au@Pt Core/Shell nanoparticle (Au@PtNPs)-based ICSs (G-ICSs). The resulting G-ICSs enabled the convenient and quantitative assessment of a target protein using the naked eye, without the need for auxiliary equipment or complicated computation. To assess this platform, C-reactive protein (CRP), a biomarker commonly used for the diagnosis of acute, infectious diseases was chosen as a proof-of-concept test. The linear detection range (LDR) of the G-ICSs for CRP was 0.05–6.25 μg/L with a limit of detection (LOD) of 0.041 μg/L. The G-ICSs had higher sensitivity and wider LDR when compared with commonly used AuNPs and fluorescent-based ICSs. When compared with results from a chemiluminescent immunoassay, G-ICS concordance rates for CRP detection in serum samples ranged from 93.72 to 110.99%. These results demonstrated that G-ICSs have wide applicability in family diagnosis and community medical institutions, especially in areas with poor medical resources.

中文翻译：

---

使用肉眼对疾病标志物进行定量评估：使用基于气体发生的生物传感器免疫层析试纸条进行即时检测

免疫层析试纸条 (ICS) 是即时检测 (POCT) 应用中常用的实用工具。然而，目前可用的ICS灵敏度较低，并且需要昂贵的设备进行定量分析。这些限制阻碍了它们在医疗资源匮乏的地区的广泛使用。我们通过将气体发生生物传感器与基于 Au@Pt 核/壳纳米粒子 (Au@PtNPs) 的 ICS (G-ICS) 集成，开发了一种新型 POCT 平台。由此产生的 G-ICS 可以使用肉眼方便、定量地评估目标蛋白，无需辅助设备或复杂的计算。为了评估该平台，选择 C ​​反应蛋白（CRP）（一种常用于诊断急性传染病的生物标志物）作为概念验证测试。G-ICS 对 CRP 的线性检测范围 (LDR) 为 0.05–6.25 μg/L，检测限 (LOD) 为 0.041 μg/L。与常用的 AuNP 和基于荧光的 ICS 相比，G-ICS 具有更高的灵敏度和更宽的 LDR。与化学发光免疫分析结果相比，血清样本中 CRP 检测的 G-ICS 一致性率为 93.72% 至 110.99%。这些结果表明，G-ICS在家庭诊断和社区医疗机构，特别是在医疗资源匮乏的地区具有广泛的适用性。